Back to Journals » Cancer Management and Research » Volume 12

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum]

Authors Yang X, Hou Z, Zhu K, Zhang S, Gu X, Wang Z, Mu H, Zhou H, Chen P, Zhu X, Cui Y, Li Q, Li H, Zhang T

Received 21 May 2020

Accepted for publication 21 May 2020

Published 3 June 2020 Volume 2020:12 Pages 4169—4170

DOI https://doi.org/10.2147/CMAR.S263933


Yang X, Hou Z, Zhu K, et al. Cancer Manag Res.  2020;12:3163– 3173.

The authors have advised there is an error with Figure 2 on page 3170. The figure parts C-H do not match the description in the figure caption or figure citations throughout the text.


The authors apologize for this error.


Read the original article

Yang X, Hou Z, Zhu K, et al. Cancer Manag Res. 2020;12:3163–3173.

The authors have advised there is an error with Figure 2 on page 3170. The figure parts C-H do not match the description in the figure caption or figure citations throughout the text.

The correct Figure 2 is shown below. The authors apologize for this error.

Figure 2 Continued.

Figure 2 Subgroup analysis of OS and PFS. (A) Subgroup with AFP >400μg/L, whether HTN can be a predictor of OS; (B) subgroup with AFP >400μg/L, whether HTN can be a predictor of PFS; (A, B) In patients with AFP ≤400μg, drug-related HTN can be used as a predictor of OS (p=0.006) and PFS (p=0.021). In patients with AFP >400μg, drug-related HTN cannot be used as a predictor of OS (p=0.081), but can be used as a predictor of PFS (p=0.007). (C) Subgroup with Child-Pugh Score, whether HTN can be a predictor of OS; (D) subgroup with Child-Pugh Score, whether HTN can be a predictor of PFS; (C, D) in patients with Child-Pugh A, drug-related HTN can be used as a predictor of OS (p=0.003) and PFS (p=0.012). In patients with Child-Pugh B, drug-related HTN cannot be used as a predictor of OS (p=0.267), but can be used as a predictor of PFS (p=0.010). (E) Subgroup with macrovascular invasion, whether HTN can be a predictor of OS; (F) subgroup with macrovascular invasion, whether HTN can be a predictor of PFS; (E, F) in patients without macrovascular invasion, drug-related HTN can be used as a predictor of OS (p=0.024), but not as a predictor of PFS (p=0.072). In patients with macrovascular invasion, drug-related HTN can be used as a predictor of OS (p=0.021) and PFS (p=0.001). (G) Subgroup with extrahepatic spread, whether HTN can be a predictor of OS; (H) subgroup with extrahepatic spread, whether HTN can be a predictor of PFS. (G, H) In patients without extrahepatic metastases, drug-related HTN cannot be used as a predictor of OS (p=0.078), but can be used as a predictor of PFS (p=0.035). In patients with extrahepatic spread, drugrelated HTN can be used as a predictor of OS (p=0.005) and PFS (p=0.000).

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]